Dublin, Ireland-based Allergan is snapping up US group Kythera Biopharmaceuticals for a cool $2.1 billion, strengthening the firm’s foothold on the facial aesthetics scene.
News
AZ signs diabetes, kidney disease deals
AstraZeneca has unveiled a duo of research deals focused on developing new therapies for diabetes and kidney disease.
EU approves Sanofi’s new Gardasil jab
A new version of Sanofi Pasteur MSD’s Gardasil has been approved by European regulators for protection against nine strains of the human papillomavirus, covering more types than any other HPV vaccine on the market.
GSK sinks $95m into pioneering cell research
GlaxoSmithKline is pouring $95 million into an independent, non-profit research institute tasked with pioneering a new understanding of how cells operate.
Academy medicines review to boost public confidence
The Academy of Medical Sciences is this week kicking off a review into the safety and efficacy of medicines to help restore public confidence in their use, on the suggestion of England’s chief medical officer Dame Sally Davies.
Bayer and John Hopkins in ophthalmic research pact
Bayer has signed a five-year pact with John Hopkins University to seek out and develop new therapies for eye conditions and beef up its ophthalmic portfolio.
Big pharma lacking in new antibiotic patents
The antibiotics market is at risk of losing another decade to inadequate levels of research and innovation in favour of rare disease drugs, according to a new study.
FDA approves first nasal migraine spray for school agers
US regulators have green-lighted the use of Impax’ Zomig to treat migraine in patients aged 12 years and older, marking approval of the first nasally-delivered prescription medicine for this age group.
FDA hooks into patient network for post-marketing drug surveillance
The US Food and Drug Administration is linking with PatientsLikeMe to gain access to patient-reported real world data that may offer new insights into drug safety.
iPod-controlled pain relief device launches
A newly-launched system for chronic pain patients is the first to use tablet devices and wireless technology to trial spinal cord stimulation therapy.
US extends review of Allergan/Gedeon Richter’s antipsychotic
US regulators have extended their review of Allergan/Gedeon Richter’s investigational antipsychotic cariprazine by three months.
Experts call for expansion of cervical cancer screening
New research has found that around 20% of cervical cancer cases diagnosed in the UK each year are in women aged over 65, sparking calls for an extension to screening services.
FDA will review Teva’s asthma biologic reslizumab
The US Food and Drug Administration has agreed to review Teva’s biologic reslizumab as a potential treatment for eosinophilic asthma.
Genzyme kicks off paediatric trial of olipudase alfa
Sanofi group Gemzyme has kicked off a Phase I/II assessing its investigational enzyme replacement therapy olipudase alfa in children with rare genetic lysosomal storage disease.
Mental health crisis services in England ‘struggling’, CQC finds
A damning report by the Care Quality Commission has found variation and inconsistency in the quality of care given to mental health patients experiencing crisis episodes across England.
